We observed that although CD3-CAR in the CAR-T-cell framework had higher in vitro activity than CD5-CAR, they were less active to reduce the tumor burden in a xenograft model, and this correlated with reduced CD3 cell surface levels after CAR treatment. This evidence concerns the gene CD5 and neoplasm.